Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.68 |
| ▸ | PPARG | P37231 | 2/20 | 0.66 |
| ▸ | PPARD | Q03181 | 2/20 | 0.66 |
| ▸ | PPARA | Q07869 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.59 |
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.59 |
| ▸ | BCHE | P06276 | 6/20 | 0.56 |
| ▸ | ACHE | P22303 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25203622 | 0.96 | GRM2 (0.66) | GRM2PPARGPPARDPPARALMNA | |
| SCHEMBL11043538 | 0.87 | PPARG (0.72) | GRM2PPARGPPARDPPARALMNA | |
| SCHEMBL11043542 | 0.87 | PPARG (0.72) | GRM2PPARGPPARDPPARALMNA | |
| SCHEMBL5032476 | 0.85 | GRM2 (0.72) | GRM2PPARGPPARDPPARALMNA | |
| SCHEMBL5032472 | 0.85 | GRM2 (0.72) | GRM2PPARGPPARDPPARALMNA | |
| SCHEMBL10744397 | 0.84 | GRM2 (0.95) | GRM2PPARGPPARDPPARALMNA | |
| SCHEMBL11047154 | 0.82 | CYSLTR2 (0.71) | GRM2PPARGPPARDPPARALMNA | |
| SCHEMBL11047150 | 0.82 | CYSLTR2 (0.71) | GRM2PPARGPPARDPPARALMNA | |
| SCHEMBL9043028 | 0.82 | GRM2 (0.80) | GRM2PPARGPPARDPPARALMNA | |
| Propionic Acid SCHEMBL11043565 | 0.82 | PPARG (0.79) | GRM2PPARGPPARDPPARALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | GRM2 4882/4885PPARG 4105/4885PPARD 2675/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | GRM2 4883/4885PPARG 3395/4885PPARD 3892/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | GRM2 4883/4885PPARG 3395/4885PPARD 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.